As September concludes, the landscape of hematologic oncology continues to evolve, spanning the full spectrum of blood cancer ...
Subcutaneous isatuximab plus bortezomib, lenalidomide, and dexamethasone is effective in transplant-ineligible, newly diagnosed multiple myeloma.
A growing list of contemporary phase 3 trials have shown that more drugs (quadruplet therapies) are superior to less drugs ...
Using steroids for longer than 6 months to treat vernal keratoconjunctivitis significantly increases the risk for steroid-induced glaucoma, even with lower-potency steroids, according to a study ...
More than half of adults who underwent a unilateral adrenalectomy to treat mild autonomous cortisol secretion developed adrenal insufficiency, according to data published in The Journal of Clinical ...
Cystatin C is an emerging biomarker that enhances kidney function assessment accuracy, particularly in hospitalized patients ...
ZTlido ® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba ® is the subject of an exclusive, transferable license to use the ...
Orthopaedic surgeons warn of a surge in avascular necrosis and fragile bones among survivors, triggered by steroids and ...
Learn more about whether Ocular Therapeutix, Inc. or Tilray Brands, Inc. is a better investment based on AAII's A+ Investor ...
From more than 30 target action dates in the last three months of the year, BioSpace has narrowed the list to six regulatory ...
Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma ...
Findings suggest bispecific CD3xCD20 therapy may offer an option for patients with Richter syndrome who are ineligible for transplant or CAR T-cell Therapy. A recent case report published in Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback